Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery

J Pain Symptom Manage. 2010 Jun;39(6):e2-4. doi: 10.1016/j.jpainsymman.2010.02.004.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents, Phytogenic / adverse effects
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects*
  • Carboplatin / therapeutic use
  • Female
  • Humans
  • Methanol / therapeutic use*
  • Ovarian Neoplasms / complications
  • Ovarian Neoplasms / drug therapy
  • Paclitaxel / adverse effects
  • Paclitaxel / therapeutic use
  • Pain Measurement / drug effects
  • Peripheral Nervous System Diseases / chemically induced*
  • Peripheral Nervous System Diseases / prevention & control*
  • TRPM Cation Channels / agonists*

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • TRPM Cation Channels
  • TRPM8 protein, human
  • Carboplatin
  • Paclitaxel
  • Methanol